Faculty

Institution

Unit

Venue

Michael G. Rosenblum

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Experimental Therapeutics

Michael G. Rosenblum is currently serving as an Experimental Therapeutics Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael G. Rosenblum

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

immunology therapeutic targets cell biology tumor targeting cancer research cancer cells pharmacology oncology cancer immunotherapy immunotherapy tumor biology medicinal research cancer biology cellular therapy oncogenes cancer treatment molecular cancer anti-cancer agents drug targeting melanoma pathology leukemia cancer imaging toxins immune responses experimental medicine cell death pharmacotherapy in vitro toxicology cancer care immunomodulation hematology hematological malignancies photomedicine vascular biology lymphoid neoplasia angiogenesis cancer growth apoptosis antibody engineering cancer immunosurveillance theranostics pharmacological research colorectal cancer novel therapies oncologic imaging therapeutic vaccines breast oncology therapeutic efficacy cancer patients tumor necrosis factor targeted delivery clinical immunology photodynamic therapy clinical mycology antifungal agents clinical pharmacology amphotericin b monoclonal antibody tissue distribution angiology therapeutic nanomaterials translational molecular imaging renal function in vivo systems myeloid neoplasia systemic fungal infections metastatic colorectal cancer malignant b cells rgel/blys fusion toxin metastatic melanoma preliminary study 99mtc-labeled liposomes vegf receptor liposomal muramyl noninvasive monitoring

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 2603: Targeting Chemo-Resistant Ovarian Cancer With a First-In-Class, First-In-Human Immune-Oncology Agents Containing Granzyme B. Cancer Research (2024)

cancer immunotherapytumor targetingovarian cancerdrug targetinganti-cancer agentsimmunologyimmunotherapyimmune checkpoint inhibitorsgynecologic oncologygynecologytherapeutic targets

Abstract 2606: Targeting Mesothelin on Tumor Cells With a Novel, Completely Human Fusion Construct Delivering the Serine Protease Granzyme B. Cancer Research (2024)

cell biologytumor targetingtherapeutic targetscancer cells

Abstract 5974: Targeting Vegfr on Tumor Cells and Activated Vasculature Through Delivery of Granzyme B. Cancer Research (2024)

pharmacologytumor targetingmolecular cancercancer cellsoncogenesmolecular medicinedrug targetingdrug deliverytumor biologyimmunologyvascular biologygranzyme bcell biologyangiogenesisabstract 5974tumor cellstherapeutic targets

Grb-Fc-Ks49, an Anti-Emp2 Granzyme B Fusion Protein Therapeutic Alters Immune Cell Infiltration and Suppresses Breast Cancer Growth. Journal for ImmunoTherapy of Cancer (2024)

Khalid A MohamedaliBrian AguirreCheng-Hsiang LuAnubhav ChandlaNidhi KejriwalLucia LiuAnn M ChanLawrence H CheungSuYin KokSergio DuarteAna Alvarez de CienfuegosDavid CaseroMichael G RosenblumMadhuri Wadehra

cancer immunotherapycancer treatmentbreast cancerimmunologyimmunotherapy

Abstract 3901: Identification of Genomic Pathways Associated With Resistance of Nsclc to Immunotherapies Containing Granzyme B. Cancer Research (2023)

Ana Alvarez-CienfuegosLawrence H. CheungKhalid A. MohamedaliGaniraju C. ManyamJing WangJohn V. HeymachMichael G. Rosenblum

cell biologycancer biologygenetic basismolecular cancergenomicscancer researchcancer genomicsgenome biologycarcinogenesiscancer treatmentoncologycancer geneticsimmunologycancer immunotherapyoncogenesgenomic pathwaysradiation oncologyleukemiamedicinal research

Abstract 6313: Ind-Enabling Studies for Grb-Fc-It4: In Vivo Efficacy, Pharmacokinetics, Schedule Optimization and Maximum Tolerated Dose. Cancer Research (2023)

medicinecancer researchoncologymetronomic therapypharmacotherapypreclinical drug evaluationmetronomic chemotherapy

Abstract 6314: Novel Granzyme B-Based Fusion Constructs Targeting Frα on Liquid and Solid Tumors. Cancer Research (2023)

Ana Alvarez-CienfuegosLawrence H. CheungKhalid A. MohamedaliNatalia BaranMarina KonoplevaMichael G. Rosenblum

cancer researchbiomolecular engineeringcancer biologysolid tumors

Abstract 6315: Human Granzyme B Fusions Targeting Vegfr on Tumor Cells and Activated Vasculature. Cancer Research (2023)

pathologytumor targetingcancer cellsoncogenesactivated vasculaturedrug targetingabstract 6315tumor biologycell biologyangiogenesistumor cellstherapeutic targets

Abstract 6316: In Vitro and in Vivo Studies of Human Granzyme B Fusion Constructs Targeting Mesothelin. Cancer Research (2023)

cancer immunotherapytumor targetingcancer cellscancer researchleukemiamolecular biologyimmunologycell biologytherapeutic targets

Abstract 6317: Targeting Cell-Surface Cea With a Novel Human Fusion Construct Delivers the Serine Protease Granzyme B to Solid Tumor Cells. Cancer Research (2023)

cancer biologytumor targetingcancer cellsoncogenesabstract 6317cancer researchdrug targetingbiomolecular engineeringcellular therapytumor biologycell researchcell-surface ceacell biologytumor cellstherapeutic targetscancer growth

1
2
3
4
5
25
10 / page

Michael G. Rosenblum

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Experimental Therapeutics

Michael G. Rosenblum is currently serving as an Experimental Therapeutics Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Michael G. Rosenblum

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 2603: Targeting Chemo-Resistant Ovarian Cancer With a First-In-Class, First-In-Human Immune-Oncology Agents Containing Granzyme B. Cancer Research (2024)

cancer immunotherapytumor targetingovarian cancerdrug targetinganti-cancer agentsimmunologyimmunotherapyimmune checkpoint inhibitorsgynecologic oncologygynecologytherapeutic targets

Abstract 2606: Targeting Mesothelin on Tumor Cells With a Novel, Completely Human Fusion Construct Delivering the Serine Protease Granzyme B. Cancer Research (2024)

cell biologytumor targetingtherapeutic targetscancer cells

Abstract 5974: Targeting Vegfr on Tumor Cells and Activated Vasculature Through Delivery of Granzyme B. Cancer Research (2024)

Grb-Fc-Ks49, an Anti-Emp2 Granzyme B Fusion Protein Therapeutic Alters Immune Cell Infiltration and Suppresses Breast Cancer Growth. Journal for ImmunoTherapy of Cancer (2024)

cancer immunotherapycancer treatmentbreast cancerimmunologyimmunotherapy

Abstract 3901: Identification of Genomic Pathways Associated With Resistance of Nsclc to Immunotherapies Containing Granzyme B. Cancer Research (2023)

Ana Alvarez-CienfuegosLawrence H. CheungKhalid A. MohamedaliGaniraju C. ManyamJing WangJohn V. HeymachMichael G. Rosenblum

Abstract 6313: Ind-Enabling Studies for Grb-Fc-It4: In Vivo Efficacy, Pharmacokinetics, Schedule Optimization and Maximum Tolerated Dose. Cancer Research (2023)

medicinecancer researchoncologymetronomic therapypharmacotherapypreclinical drug evaluationmetronomic chemotherapy

Abstract 6314: Novel Granzyme B-Based Fusion Constructs Targeting Frα on Liquid and Solid Tumors. Cancer Research (2023)

Ana Alvarez-CienfuegosLawrence H. CheungKhalid A. MohamedaliNatalia BaranMarina KonoplevaMichael G. Rosenblum

cancer researchbiomolecular engineeringcancer biologysolid tumors

Abstract 6315: Human Granzyme B Fusions Targeting Vegfr on Tumor Cells and Activated Vasculature. Cancer Research (2023)

pathologytumor targetingcancer cellsoncogenesactivated vasculaturedrug targetingabstract 6315tumor biologycell biologyangiogenesistumor cellstherapeutic targets

Abstract 6316: In Vitro and in Vivo Studies of Human Granzyme B Fusion Constructs Targeting Mesothelin. Cancer Research (2023)

cancer immunotherapytumor targetingcancer cellscancer researchleukemiamolecular biologyimmunologycell biologytherapeutic targets

Abstract 6317: Targeting Cell-Surface Cea With a Novel Human Fusion Construct Delivers the Serine Protease Granzyme B to Solid Tumor Cells. Cancer Research (2023)

1
2
3
4
5
25
10 / page